相关临床试验
115
32 进行中
药物批准
88
批准总数
监管机构
4
监管机构数
成立时间
1983
进行中（未招募）
6
5.2%
已完成
70
60.9%
尚未招募
26
22.6%
招募中
4
3.5%
暂停
2
1.7%
Unknown
2
1.7%
- New comprehensive market reviews reveal robust clinical trial activity for both gouty arthritis (gout) and bronchiectasis, with major pharmaceutical companies leading development efforts across multiple regions. - The reports highlight significant participation from industry leaders including AstraZeneca, Novartis, and Takeda in gout research, while bronchiectasis trials feature prominent involvement from Boehringer Ingelheim, Insmed, and Gilead Sciences. - Both therapeutic areas demonstrate global research distribution across G7 and E7 countries, with detailed analysis of trial phases, enrollment trends, and sponsor participation patterns. - Recent developments include Vast Therapeutics completing its first milestone in a Phase 1 clinical program for bronchiectasis treatment in November 2025.
- The US FDA issued eight observations to Sun Pharma's Halol manufacturing facility in Gujarat following a Good Manufacturing Practices inspection conducted from June 2-13, 2025. - The facility has been under an import alert since May 2022 and remains classified as OAI (Official Action Indicated) since March 2020, restricting exports to the US market. - Despite the regulatory challenges, UBS maintains a buy rating with a target price of Rs 2,450, while Nomura expects limited impact from potential site resolution given the company's large revenue base. - Sun Pharma announced a leadership transition with Kirti Ganorkar becoming Managing Director effective September 1, 2025, while founder Dilip Shanghvi will continue as Executive Chairman.
- Sun Pharmaceutical Industries Ltd has announced a strategic $25 million investment in US-based Pharmazz Inc, increasing its ownership stake to 22.7% in the biopharmaceutical company. - The investment will be completed in stages, with an initial $10 million tranche plus $7.5 million from a previous agreement by May 2025, and an additional $15 million expected by November 2025. - Through this investment, Sun Pharma secures exclusive rights to market Sovateltide in select emerging markets and gains options to negotiate licensing rights in certain developed countries.
- The U.S. Court of Appeals for the Federal Circuit has vacated a preliminary injunction against Sun Pharma, allowing the company to proceed with launching Leqselvi (deuruxolitinib) for alopecia areata in the American market. - Sun Pharma acquired Leqselvi through its $576 million Concert Pharma acquisition in 2023, positioning it as a key product in its specialty portfolio that recently surpassed $1 billion in annual sales. - The patent infringement litigation with Incyte Corporation continues, but Sun Pharma is no longer restricted from launching the drug, which analysts project could contribute $90 million to sales in FY26 and $125 million in FY27.
